Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416360 | 0.92 | CYP11B2 (0.47) | CYP11B2KMT2AMCHR1KCNH2FPR2 | |
| SCHEMBL16763611 | 0.92 | CYP11B2 (0.47) | CYP11B2KMT2AMCHR1KCNH2FPR2 | |
| SCHEMBL15415872 | 0.79 | PDE10A (0.44) | CYP11B2MCHR1KCNH2EP300JAK2 | |
| SCHEMBL15416560 | 0.79 | CYP11B2 (0.41) | CYP11B2KMT2AMCHR1KCNH2FPR2 | |
| SCHEMBL24165560 | 0.78 | CYP11B2 (0.46) | CYP11B2KMT2AMCHR1KCNH2FPR2 | |
| SCHEMBL15415417 | 0.77 | CYP11B2 (0.40) | CYP11B2MCHR1KCNH2JAK2CCR3 | |
| SCHEMBL16512912 | 0.77 | CCR3 (0.48) | CYP11B2MCHR1KCNH2FPR2BACE1 | |
| SCHEMBL18807889 | 0.77 | CYP11B2 (0.43) | CYP11B2MCHR1KCNH2FPR2TBXA2R | |
| SCHEMBL22495117 | 0.77 | FPR2 (0.47) | CYP11B2FPR2EP300TBXA2RHDAC6 | |
| SCHEMBL19470928 | 0.76 | CYP11B2 (0.49) | CYP11B2MCHR1KCNH2EP300CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | CYP11B2 526/4885KMT2A 2954/4885MCHR1 1636/4885 |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | CYP11B2 526/4885KMT2A 2954/4885MCHR1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.